European to US expansion Leverage Diabeloop's CE marking and FDA 510(k) clearance for DBLG2 to target not only Europe but also enter the US market through strategic partnerships with Sequel Med Tech and Tingo Medical, highlighting growth potential in interopable automated insulin delivery solutions.

Interoperable AI scale Position DBLG2 as an interoperable AID platform that integrates with Dexcom G7 CGM and various insulin pumps, offering a compelling selling point to clinics and payers seeking flexible, scalable diabetes management automation with proven TIR improvements.

Strategic partnerships Emphasize ongoing collaboration opportunities with US and international partners to co-develop and co-market AI-driven diabetes management solutions, reducing time to market and expanding installed patient bases across regions.

Clinical outcomes focus Highlight demonstrated clinical benefits such as increased Time in Range and reduced hypoglycemia to persuade stakeholders (providers, hospitals, clinics, and payers) of improved patient outcomes and potential cost savings.

Demo driven Utilize the DBLG2 Demo App release to support sales conversations with clinicians and procurement teams, offering a tangible, risk-free way to experience automated insulin delivery simulations and validate fit with existing workflows.